Immunome (IMNM) stock

Oncology therapies , market cap $2.1B

Oncology therapies

Worth $2.1B

$18.65

-3.67%

FDA in 169 daysEvery upcoming FDA date ›

As of Tuesday's close · Live for Pro members at the open

Why is IMNM down?

Down 26% in 3 months, 9% under its 50-day average.

Down more than its industry: the 274 other stocks in it fell a median 13% over the same 3 months.

−2Dilution 29.1% more shares outstanding than a year ago

Tell me next time IMNM moves

Free account, no card. An optional alert when IMNM moves or its score changes.

Or see it live, free until Thursday morning. No account.

5 more things pulling IMNM's score down, for Pro members.

Quality Score

-7

Poor

In its industry

#242of 281

Biotech

Checks firing

0of 14

Trending down

From 52-week high

-38.0%

under its best in a year

IMNM's Quality Score fell 2 points on Tue, Nov 10, to -7. Its average price of the last 21 days started to slip (2 chart checks stopped).

Follow IMNM's trial news. Pro members can get an alert when Immunome files news, and see its trials, share raises, and its CEO's filings.

Get an alert when IMNM files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextApr 28, 2027 · In 169 days…or FDA, and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027…FDA decision date · SEC filing · Nov 9

Cash$462M, about 8 quarters (2 years) at the last year's spendingOn Sep 30

Key facts on IMNM

Key facts on IMNM
Holding it back	29.1% more shares than a year ago
Latest filing	8-K, Nov 9 Reported its quarterly results

1 more reason behind IMNM's -7, free with an account →3 more reasons behind IMNM's -7, for Pro members.

IMNM in the news

ReportLast night: a loss of $0.76 a share. Past reports ›

What's next

Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$462M, about 8 quarters (2 years) at the last year's spendingOn Sep 30

IMNM catalysts

Coming up

After its last 4 reports it closed +1.3% on average, higher 2 of 4 times.

4 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for IMNM, and how long its cash lasts

Next step the company has named

Apr 28, 2027In 169 days…in April 2026, which has been accepted by the U.S. Food and Drug Administration, or FDA, and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027.FDA decision date · SEC filing · Nov 9

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

A trial underway: Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy ParticipantsPhase 1 · Recruiting · 44 people · main data estimated May 2027 · NCT07610005

5 more trials, 37 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 8 quarters

$462M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: whether the cash lasts past the FDA date, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Nov 9, 2026)
At-the-market share sales program (S-3ASR, filed Nov 9, 2026)

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

Chief Scientific Officer Jack Higgins sold 13,200 shares on Sep 11, under a planned sale. 17 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Clay Siegall buys or sells

For Pro members: every trade, and Clay Siegall’s 9 filings and quotes.

Get an alert before IMNM's FDA date

A free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

How IMNM ranks in Biotech

IMNM is #242 of 281 by Quality Score.

How IMNM ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	IMCRImmunocore		Open for its score
	IMMXImmix Biopharma		Open for its score
	IMRXImmuneering		Open for its score
	IMUXImmunic		Open for its score
242	IMNMImmunome	0/14	-7

Sales over four quarters against a year before: IMNM -100%, ZYME +98%, ABCL +92%, TNGX -100%.

When does IMNM report earnings, and what happens after?

Expected to report Wed Mar 3, after the close (in 113 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What IMNM reported on Nov 9, 2026

The quarter

A loss of $0.76 a share, from $0.65.

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

IMNM's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value: $2.1B; today
Sales: $0; down 100% on the year
Free cash flow: -$239M; last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on IMNM: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-2.2%+6.6%-3.7%

May 12Aug 11Nov 9

Reported	When	Gap	Reaction	5 days
Nov 9, 2026After close	After close	-6.5%	-3.7%	not yet
Aug 11, 2026After close	After close	-3.9%	+6.6%	+5.0%
May 12, 2026After close	After close	+3.1%	-2.2%	-13.3%

IMNM closed higher after 2 of its last 4 reports.

All 4 reports, and IMNM's Quality Score going into each

IMNM sales and profit by year

Sales and profit by year

Sales fell every year from 2023 to 2025, to $6.9M. It lost money in each of the three years.

Nothing is firing on IMNM right now

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on IMNM, and all 14 on every stock.Get in free →

IMNM RSI today: 46.0, below its 50-day and 200-day averages

Not scored

RSI 46.0, MACD above signal, below both averages. Not scored.13 readings

The deep dive on IMNM

What it does and how it makes money4 findingsAn operating loss of $224M in fiscal 2025, on $6.94M of sales.Annual report, filed Mar 3, 2026"In exchange for such license, BMS must pay us a low single-digit percentage royalty on net sales of the BMS Licensed Compounds and/or BMS Licensed Products by it or its affiliates …" (10-K for fiscal 2025)SEC filing · Mar 3, 2026"The US composition of matter patent covering varegacestat will expire in 2038, which includes 5 years of expected patent term extension." (10-K for fiscal 2025)SEC filing · Mar 3, 2026
Where it stands3 findingsFor Pro members3 findings on where IMNM stands: its cash, debt, and share count, for Pro members
What changed in its filings2 findingsNew in its "Risk Factors" this year: "We cannot predict the nature or extent of any impact that the acquisition of SpringWorks by Merck KGaA will have on the competitive landscape for varegacestat." (10-K for fiscal 2025)SEC filing · Mar 3, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades IMNM, for Pro members
Against its closest peers3 peersSales over four quarters against a year before: IMNM -100%, ZYME +98%, ABCL +92%, TNGX -100%.

7 more findings on IMNM, each with its source, for Pro members.

IMNM share count over time

29% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of IMNM outstanding, as filed
Shares outstanding	As of
118.1M	Nov 4, 2026
113.6M	Aug 6, 2026
113.3M	May 7, 2026
113.1M	Feb 27, 2026

Offerings, shelves, and splits of IMNM, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Nov 9, 2026
Raised $400.4M in a sale of shares, about 19% of its market value	Dec 17, 2025
Raised $150M in a sale of shares, about 7% of its market value	Jan 30, 2025
Registered shares for a later sale (S-3ASR)	Nov 22, 2024

6 more offerings on file, for Pro members.

IMNM insider trades

One insider bought $308K across 4 filings, and one insider sold $204K across 2 filings, in the last 6 months. The newest:

SellJean Jacques Bienaime$194KDirectorat $19.41 on Jun 5, filed Jun 9

SellJean Jacques BienaimeDirector$194Kat $19.41 on Jun 5, filed Jun 9

All 6 insider filings on IMNM from the last six months, for Pro members.

All IMNM insider trades

IMNM's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Clay B. SiegallPresident and CEO · 3 trades
Max RosettChief Financial Officer · 2 trades
Jack HigginsChief Scientific Officer · 2 trades
Kinney HornChief Business Officer · 2 trades
Robert LechleiderChief Medical Officer · 2 trades
Philip TsaiChief Technical Officer · 1 trade
Sandra G. StonemanChief Legal Officer & GC · no trades on file
Isaac BarchasDirector · 10 trades

3 more officers and directors file at IMNM.

See insider trades by person

Which ETFs hold IMNM?

In ETFs: IMNM is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Immunome

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

177 employeesBothell, WAimmunome.com

What Immunome says it competes with

“The development and commercialization of new product candidates is highly competitive.”

From its annual report, SEC filing · Mar 3, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on IMNM and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn IMNM's score around: 9 things
13 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJun 9Jean Jacques Bienaime bought IMNM$117K at $19.48, filed Jun 9

Alerts are optional.

See IMNM's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: IMNM's Quality Score is -7 (Poor), #242 of 281 in Biotech. Insiders bought $308K and sold $204K in the last 6 months (Form 4).

What does IMNM's Quality Score say?

IMNM scores -7 today, which Breakaway calls Poor. It is #242 of 281 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 26% in 3 months, 9% under its 50-⁠day average. Cash lasts about 8 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is IMNM's Quality Score?

IMNM scores -7 today, which Breakaway calls Poor (below zero). That is #242 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IMNM's -7.

Are insiders buying IMNM?

One insider bought $308K across 4 filings, and one insider sold $204K across 2 filings, in the last 6 months. The newest is Jean Jacques Bienaime, Director, who sold $194K on Jun 5. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.